B. Lichty

发表

Going viral with cancer immunotherapy

C. Breitbach, J. Bell, B. Lichty, 2014, Nature Reviews Cancer.

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

Nahum Sonenberg, H. Atkins, N. Sonenberg, 2000, Nature Medicine.

Targeting tumor vasculature with an oncolytic virus.

H. Atkins, A. Fenster, D. Kirn, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Immunological considerations for COVID-19 vaccine strategies

Matthew S. Miller, B. Lichty, M. Jeyanathan, 2020, Nature Reviews Immunology.

Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning

G. Kroemer, S. Workenhe, B. Lichty, 2020, Journal for ImmunoTherapy of Cancer.

Intelligent Design: Combination Therapy With Oncolytic Viruses.

J. Diallo, J. Bell, B. Lichty, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Intelligent design: combination therapy with oncolytic viruses.

J. Diallo, J. Bell, B. Lichty, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Maraba virus as a potent oncolytic vaccine vector.

Liang Zhang, B. Lichty, D. Stojdl, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity.

J. Boudreau, B. Lichty, J. Bramson, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Endogenous T cells prevent tumor immune escape following adoptive T cell therapy.

B. Lichty, J. Bramson, K. Stephenson, 2019, The Journal of clinical investigation.

Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy.

H. Atkins, D. Roy, J. Bell, 2015, Journal of controlled release : official journal of the Controlled Release Society.

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

H. Atkins, J. Hiscott, J. Bell, 2003, Cancer cell.

Vesicular stomatitis virus: re-inventing the bullet.

J. Bell, B. Lichty, D. Stojdl, 2004, Trends in molecular medicine.

Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization.

B. Lichty, Z. Xing, 2006, Tuberculosis.

Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages

U. Rapp, S. Ludwig, V. Wixler, 2018, Oncoimmunology.

ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic.

H. Atkins, P. Ohashi, A. Mercer, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Expression of p210 and p190 BCR‐ABL due to alternative splicing in chronic myelogenous leukaemia

S. Kamel‐Reid, K. Yee, A. Keating, 1998, British journal of haematology.

Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy

S. Workenhe, B. Lichty, Jonathan G. Pol, 2013, Cancer Immunology Research.

Cigarette smoke suppresses type I interferon-mediated antiviral immunity in lung fibroblast and epithelial cells.

C. Bauer, M. Stämpfli, B. Lichty, 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Cancer immunology and canine malignant melanoma: A comparative review.

Joanna S Morris, B. Lichty, M. McDermott, 2016, Veterinary immunology and immunopathology.

Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression

B. Lichty, B. Johnston, S. Gebremeskel, 2022, Journal for ImmunoTherapy of Cancer.

Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats

B. Lichty, D. Bienzle, K. Stephenson, 2017, Scientific Reports.

Oncolytic Viruses: Therapeutics With an Identity Crisis

C. Breitbach, J. Bell, B. Lichty, 2016, EBioMedicine.

Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity

A. Ashkar, B. Lichty, K. Stephenson, 2011, Cancer Gene Therapy.

Strategies to enhance viral penetration of solid tumors.

Elspeth B. Smith, B. Lichty, Jessica A. Breznik, 2011, Human gene therapy.

Vesicular Stomatitis Virus Oncolytic Treatment Interferes with Tumor-Associated Dendritic Cell Functions and Abrogates Tumor Antigen Presentation

J. Hiscott, B. Lichty, Marie-Line Goulet, 2011, Journal of Virology.

Panorama From the Oncolytic Virotherapy Summit: 7th International Summit on Oncolytic Viral Therapeutics Quebec, Canada, 15-18 June 2013.

J. Bell, B. Lichty, R. Arulanandam, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.

W. Halford, S. Workenhe, B. Lichty, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Synergistic interaction between oncolytic viruses augments tumor killing.

H. Atkins, J. Diallo, D. Kirn, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers.

H. Atkins, E. Brown, J. Diallo, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination

Sandeep T. Koshy, Derek L. Clouthier, Liang Zhang, 2016, The Journal of Immunology.

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy

J. Diallo, D. Roy, J. Bell, 2018, Science Translational Medicine.

Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.

J. Boudreau, Sandeep T. Koshy, B. Lichty, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Transforming the prostatic tumor microenvironment with oncolytic virotherapy

F. Saad, R. Breau, F. Tzelepis, 2018, Oncoimmunology.

Immunotherapy Can Reject Intracranial Tumor Cells without Damaging the Brain despite Sharing the Target Antigen

Shucui Jiang, B. Lichty, J. Bramson, 2010, The Journal of Immunology.

Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines

Derek L. Clouthier, Liang Zhang, B. Lichty, 2013, Oncoimmunology.

Development and applications of oncolytic Maraba virus vaccines

J. Diallo, C. Breitbach, J. Bell, 2018, Oncolytic virotherapy.

Single-dose respiratory mucosal delivery of next-generation viral-vectored COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

M. Jordana, Ramandeep Singh, Fuan Wang, 2021, bioRxiv.

Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

Matthew S. Miller, M. Jordana, Ramandeep Singh, 2022, Cell.

Cutting Edge: FimH Adhesin of Type 1 Fimbriae Is a Novel TLR4 Ligand1

A. Ashkar, B. Lichty, K. Mossman, 2008, The Journal of Immunology.

Cutting Edge Cutting Edge : FimH Adhesin of Type 1 Fimbriae Is a Novel TLR 4 Ligand 1

A. Ashkar, B. Lichty, K. Mossman, 2008 .

Cigarette smoke impacts immune inflammatory responses to influenza in mice.

Carla M. T. Bauer, C. Bauer, M. Stämpfli, 2006, American journal of respiratory and critical care medicine.

Probing effects of additives on the filterability of oncolytic viruses via a microfiltration process

David R. Latulippe, B. Lichty, M. Medina, 2020 .

Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination.

B. Lichty, Jonathan G. Pol, B. Bridle, 2020, Methods in molecular biology.

Oncolytic viruses: programmable tumour hunters.

J. Bell, K. Garson, B. Lichty, 2002, Current gene therapy.

Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination

D. Roy, J. Bell, B. Lichty, 2021, Nature Communications.

the Target Antigen Damaging the Brain despite Sharing Intracranial Tumor Cells without Immunotherapy Can Reject

Shucui Jiang, B. Lichty, J. Bramson, 2010 .

Correction: Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence

L. Tai, J. Bell, Kelley A. Parato, 2016, PloS one.

Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence

L. Tai, J. Bell, Kelley A. Parato, 2016, PloS one.

Mucosal Luminal Manipulation of T Cell Geography Switches on Protective Efficacy by Otherwise Ineffective Parenteral Genetic Immunization1

B. Lichty, Z. Xing, S. McCormick, 2007, The Journal of Immunology.

Immunizationby Otherwise Ineffective Parenteral Genetic Geography Switches on Protective Efficacy Mucosal Luminal Manipulation of T Cell

B. Lichty, Z. Xing, S. McCormick, 2007 .

The p14 FAST Protein of Reptilian Reovirus Increases Vesicular Stomatitis Virus Neuropathogenesis

J. Bell, R. Duncan, B. Lichty, 2008, Journal of Virology.

Excipient selection for thermally stable enveloped and non‐enveloped viral vaccine platforms in dry powders

Matthew S. Miller, C. Fradin, E. Cranston, 2019, International journal of pharmaceutics.

A critical role for IL‐15 in TLR‐mediated innate antiviral immunity against genital HSV‐2 infection

A. Ashkar, B. Lichty, K. Mossman, 2011, Immunology and cell biology.

Matrix protein of Vesicular stomatitis virus harbours a cryptic mitochondrial-targeting motif.

H. McBride, J. Bell, B. Lichty, 2006, The Journal of general virology.

Infectious Optimism following the 10th International Oncolytic Virus Meeting

R. Vile, J. Bell, B. Lichty, 2017 .

Sterile filtration of oncolytic viruses: an analysis of effects of membrane morphology on fouling and product recovery

David R. Latulippe, I. Gough, J. Bell, 2018 .

Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia.

D. Spaner, B. Lichty, J. Tomić, 2011, Blood.

CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX

J. Diallo, J. Whelan, G. Pugliese, 2023, Frontiers in Immunology.

Comparison of the performance of anion exchange membrane materials for adenovirus purification using laterally-fed membrane chromatography

David R. Latulippe, B. Lichty, M. Medina, 2022, Biochemical Engineering Journal.

Purification of therapeutic adenoviruses using laterally-fed membrane chromatography

David R. Latulippe, B. Lichty, M. Medina, 2019, Journal of Membrane Science.

Integrated development of enzymatic DNA digestion and membrane chromatography processes for the purification of therapeutic adenoviruses

David R. Latulippe, B. Lichty, M. Medina, 2021 .

The Murine Double-Stranded RNA-Dependent Protein Kinase PKR Is Required for Resistance to Vesicular Stomatitis Virus

N. Sonenberg, J. Bell, E. Brown, 2000, Journal of Virology.

Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans

P. O'Byrne, M. Dolovich, K. Howie, 2022, JCI insight.

Human Coronavirus OC43 Nucleocapsid Protein Binds MicroRNA 9 and Potentiates NF-κB Activation

B. Lichty, K. Stephenson, J. Mahony, 2013, Journal of Virology.

Dysregulation of HOX11 by chromosome translocations in T-cell acute lymphoblastic leukemia: a paradigm for homeobox gene involvement in human cancer.

S. Kamel‐Reid, B. Lichty, I. Dubé, 1995, Leukemia & lymphoma.

Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer

M. Seshadri, K. Odunsi, S. Battaglia, 2019, Journal of Immunotherapy for Cancer.

RNA editing enzyme APOBEC3A promotes pro-inflammatory M1 macrophage polarization

Jianmin Wang, K. Odunsi, K. Moysich, 2021, Communications biology.

RNA editing enzyme APOBEC3A promotes pro-inflammatory M1 macrophage polarization

Jianmin Wang, K. Odunsi, K. Moysich, 2020, Communications Biology.

A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication.

H. Atkins, J. Bell, T. Falls, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity

H. Atkins, J. Diallo, M. Burdick, 2015, Nature Medicine.

Exon-skipping in BCR/ABL is induced by ABL exon 2.

S. Kamel‐Reid, B. Lichty, 2000, The Biochemical journal.

Microvesicles: ubiquitous contributors to infection and immunity

B. Lichty, D. Bowdish, Frances W. Lai, 2015, Journal of leukocyte biology.

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

H. Atkins, J. Bell, Kelley A. Parato, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Oncolytic viruses: a step into cancer immunotherapy

B. Lichty, Jonathan G. Pol, Julien Rességuier, 2011 .

Virus Adaptation and Treatment Oncolytic viruses : a step into cancer immunotherapy

B. Lichty, Jonathan G. Pol, Julien Rességuier, 2011 .

Evolution of oncolytic viruses: novel strategies for cancer treatment.

B. Lichty, M. Atherton, 2013, Immunotherapy.

Induction of Innate Immunity against Herpes Simplex Virus Type 2 Infection via Local Delivery of Toll-Like Receptor Ligands Correlates with Beta Interferon Production

A. Ashkar, B. Lichty, K. Mossman, 2006, Journal of Virology.

VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

H. Atkins, J. Diallo, D. Kirn, 2015, Cancer cell.

Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses.

J. Boudreau, D. Spaner, Liang Zhang, 2013, Blood.

Potentiating cancer immunotherapy using an oncolytic virus.

Eleanor Pullenayegum, Yonghong Wan, J. Boudreau, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Heterologous Boosting of Recombinant Adenoviral Prime Immunization With a Novel Vesicular Stomatitis Virus–vectored Tuberculosis Vaccine

B. Lichty, Z. Xing, Xizhong Zhang, 2008, Molecular Therapy.

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

G. Stoll, G. Denisova, C. Breitbach, 2018, Oncoimmunology.

Consecutive Spray Drying to Produce Coated Dry Powder Vaccines Suitable for Oral Administration.

E. Cranston, B. Lichty, M. Thompson, 2018, ACS Biomaterials Science & Engineering.

S6K-STING interaction regulates cytosolic DNA–mediated activation of the transcription factor IRF3

M. Diamond, N. Sonenberg, T. Alain, 2016, Nature Immunology.

Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy.

J. Boudreau, B. Lichty, K. Mossman, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

FimH can directly activate human and murine natural killer cells via TLR4.

D. Andrews, A. Ashkar, B. Lichty, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Getting oncolytic virus therapies off the ground.

J. Bell, B. Lichty, D. Stojdl, 2003, Cancer cell.

IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells.

L. Lenz, J. Boudreau, Fuan Wang, 2011, Cancer research.

CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer

K. Odunsi, P. Shrikant, S. Battaglia, 2020, Journal for ImmunoTherapy of Cancer.

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.

Yonghong Wan, Alfredo Capretta, J. Diallo, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy.

H. Atkins, J. Bell, L. Miller, 2004, Human gene therapy.

Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.

H. Atkins, J. Diallo, B. Vanderhyden, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Treatment of permissive tumors with the oncolytic virus ( OV ) VSV-Δ 51 leads to a robust antitumor

H. Atkins, J. Diallo, B. Vanderhyden, 2012 .

Combining Oncolytic Viruses with Cancer Immunotherapy

J. Bell, B. Lichty, K. Stephenson, 2011 .

Combining oncolytic virotherapy and tumour vaccination.

B. Lichty, B. Bridle, Stephen Hanson, 2010, Cytokine & growth factor reviews.

Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSVΔM51) on Multifocal and Invasive Gliomas

T. Alain, R. Johnston, J. Bell, 2006 .

Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer.

B. Lichty, M. Atherton, K. Stephenson, 2018, Vaccine.

Customized Viral Immunotherapy for HPV-Associated Cancer

J. Diallo, S. Johnson-Obaseki, Fuan Wang, 2017, Cancer Immunology Research.

Measles Vaccines Designed for Enhanced CD8+ T Cell Activation

D. Jäger, S. Eichmüller, Johannes P. W. Heidbuechel, 2020, Viruses.

An easily adopted murine model of distal pancreatectomy for investigating immunotherapy efficacy in resectable pancreatic adenocarcinoma

L. Tai, J. Bell, B. Lichty, 2020, bioRxiv.

IL-15 Can Signal via IL-15Rα, JNK, and NF-κB To Drive RANTES Production by Myeloid Cells

N. Sonenberg, T. Alain, A. Ashkar, 2012, The Journal of Immunology.

Characterization of the Shope fibroma virus DNA ligase gene.

R. Parks, B. Lichty, D. Evans, 1994, Virology.

Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats

B. Lichty, D. Bienzle, K. Stephenson, 2017, Scientific Reports.

Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers

U. Rapp, S. Ludwig, V. Wixler, 2021, Oncoimmunology.

CXCR6 enforced retention promotes resident memory CD8 T cell- mediated immunosurveillance and control of ovarian cancer

K. Odunsi, P. Shrikant, S. Battaglia, 2021 .

Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease.

A. Makrigiannis, L. Tai, J. Bell, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

IL‐15 has innate anti‐tumor activity independent of NK and CD8 T cells

A. Ashkar, S. Reid, B. Lichty, 2010, Journal of leukocyte biology.

Using G-deleted vesicular stomatitis virus to probe the innate anti-viral response.

B. Lichty, Natasha Kazdhan, Frances W. Lai, 2008, Journal of Virological Methods.

Engraftment of human chronic lymphocytic leukemia cells in SCID mice: in vivo and in vitro studies.

S. Kamel‐Reid, B. Lichty, I. Dubé, 1996, Leukemia.

Spray dried VSV-vectored vaccine is thermally stable and immunologically active in vivo

E. Cranston, B. Lichty, M. Thompson, 2020, Scientific Reports.

Panorama from the oncolytic virotherapy summit.

J. Bell, B. Lichty, R. Arulanandam, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

CXCR6 governs the retention of tissue-resident memory T cells to promote enhanced surveillance and control of ovarian cancer

K. Odunsi, P. Shrikant, S. Battaglia, 2020 .